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ABSTRACT
Glioblastoma Multiforme (GBM) is still an incurable disease. The front-line 
Temozolomide (TMZ)-based therapy suffers from poor efficacy, underlining the need 
of new therapies.
Preclinically, Aldoxorubicin (Aldox), a novel prodrug of Doxorubicin (Dox), has 
been successfully tested against GBM, encouraging the study of its association with 
other agents.
For the first time, we evaluated the effectiveness of Aldox combined to TMZ in 
preclinical models of GBM.
Our in vitro results demonstrated that the anti–glioma effect of Aldox was 
more marked than TMZ and their combination increased the killing effect of the 
anthracycline in TMZ-resistant GBM cells. Moreover, unlike Dox, Aldox was able to 
accumulate in P-glycoprotein (P-gp)-overexpressed cells due to a negative regulation 
of the P-gp function.
We also compared efficacy and safety of weekly administrations of Aldox (16 
mg/kg), with or without TMZ (0.9 mg/kg, daily injections), in the U87 xenograft 
mouse model.
Aldox therapy induced a moderate tumor volume inhibition (TVI) and an increased 
survival rate (+12.5% vs vehicle). On the other hand, when combined to TMZ, Aldox 
caused a significant TVI (P=0.0175 vs vehicle) and delayed the mortality during the 
experimental period, although TVI and endpoint survival percentage (+37.5% vs 
vehicle) were not significantly different from TMZ alone.
Our preliminary data showed that Aldox exerts anti–glioma effects in vitro 
and in vivo. It also enhances its antitumor activity when combined with TMZ, 
resulting in a superior efficacy compared to the single agents, without adverse 
side effects.
INTRODUCTION
There is a need for new approaches that may be able to 
achieve improved outcomes in Glioblastoma (GBM) patients.
In fact, despite multimodal approach of radiotherapy 
plus concurrent and adjuvant Temozolomide (TMZ), the 
prognosis for patients has not changed significantly for over 
ten years.
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A shared issue among these malignancies that 
affects the efficacy of anticancer therapies involves the 
Blood-Brain Barrier (BBB); it represents a major hurdle 
for the delivery of drugs into the brain, contributing to the 
poor response of brain tumors to chemotherapy.
Doxorubicin (Dox) is an effective anti-glioma agent, 
but its clinical application is primarily limited by inability 
to cross the BBB [1].
At the present, various strategies have been 
emerged in order to increase the therapeutic use of the 
drug, including the incorporation in nanoscale carriers 
as liposomes, polymer and peptide/protein conjugates, 
polymeric micelles, nanoparticles [2].
An attractive new approach is a delivery system that 
exploits albumin as a drug carrier.
In 2002 Kratz and co-workers investigated 
antitumor efficacy and toxicity of four albumin-
binding Dox prodrugs, demonstrating that especially 
the (6-maleimidocaproyl)hydrazone derivative of Dox 
(Aldoxorubicin (Aldox), formerly known as INNO-206, 
CytRx Corporation), selectively bound to the cysteine-34 
position of endogenous albumin, was superior to the 
parent molecule Dox in a murine renal cell carcinoma 
model and in breast carcinoma xenograft models [3].
The study was taken further and the higher efficacy 
of Aldox compared to Dox was also demonstrated in an 
ovarian carcinoma model, in an orthotopic pancreatic 
cancer model [4], in a multiple myeloma model [5] 
and in a U87 human GBM xenograft model [6], with a 
3- to 5-fold increase in the Maximum Tolerated Dose 
(MTD) [7].
In addition, preclinical studies have showed that 
Aldox is significantly less cardiotoxic than Dox [8] and, 
unlike Dox, it is able to penetrate the BBB [6], although 
it is still unclear why covalent binding to albumin allows 
Dox to bypass the export pumps at the BBB [9].
Of note that combination protocols with Aldox and 
Dox have produced hopeful results in solid malignancies 
as ovarian and pancreatic cancer [10, 11], encouraging the 
study of association of albumin-binding drugs with other 
anticancer agents.
For malignant GBM, TMZ is the only front-line 
treatment. However, no significant improvements are 
induced by TMZ treatment on overall survival and 
the combination therapy with other drugs, found to be 
effective against gliomas [12, 13], does not appear to 
improve response or survival of GBM patients [14].
Therefore, we first investigated the combinational 
effect of Aldox and TMZ against gliomas. Thus, we have 
studied the anti-glioma activity of this novel anthracycline, 
either alone or combined to TMZ, in vitro and determined 
its efficacy on tumor regression in a xenograft model of 
human GBM. Moreover, we have verified if the addition 
of TMZ affects the cellular uptake of Aldox, focusing 
on the activity of P-glycoprotein (P-gp), one of the most 
intensively studied multidrug transporters.
RESULTS
Effect of association of TMZ with Aldox on 
GBM growth and apoptosis in vitro
We investigated the responsiveness of three GBM 
cell lines (U87MG, A172 and T98G) to the killing effect 
of the Aldox (12 μM) and TMZ (100 μM and 200 μM) 
exposure and the co-treatment Aldox plus TMZ.
Our data showed that TMZ at 100 μM was not toxic 
to all cell lines, while the higher concentration of 200 μM 
resulted to be toxic to U87MG and A172 (Figure 1A and 
1B). T98G appeared to be TMZ resistant (Figure 1C).
In contrast, Aldox significantly inhibited the 
viability of all cell lines (*P<0.01; ***P<0.0001 vs untreated 
cells).
As shown in Figure 1A and 1B, the treatment with 
Aldox resulted in a cell viability of ~50% of control in 
U87MG and A172, with a greater cytotoxicity compared 
to TMZ (###P<0.0001 vs TMZ 100 μM-treated cells; ΩΩP< 
0.001 vs TMZ 200 μM-treated cells), while T98G turned 
Figure 1: Cell viability of U87MG (A), A172 (B) and T98G (C) cells treated with Aldox, TMZ and their combination at the indicated 
concentrations for 72 h by MTT assay. Results shown are the mean % viability ± S.D. of three independent experiments. *P=<0.01; 
**=P<0.001 ***=P<0.0001 vs untreated cells; ###=P<0.0001 vs TMZ 100 μM-treated cells; ΩΩP< 0.001; ΩΩΩP< 0.0001 vs TMZ 200 μM-treated 
cells; °°°P<0.0001 vs Aldox-treated cells; ANOVA one-way followed by Bonferroni post-hoc test.
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out to be more resistant with a cell viability of ~80% of 
control (Figure 1C).
Even more interesting, the killing effect of the 
anthracycline against T98G was significantly higher in 
the presence of both low and high TMZ (°°°P<0.0001 vs 
Aldox-treated cells) (Figure 1C).
We also performed a TUNEL assay to investigate 
the pro-apoptotic effect of Aldox (12 μM) and TMZ 
(100 μM and 200 μM), as single therapy and combined 
treatment, on GBM cells.
Flow cytometry demonstrated that the rate of 
apoptosis was very lower in untreated-, 100 μM- and 200 
μM TMZ groups compared with Aldox and Aldox plus 
TMZ groups in all cell lines (**P<0.001; ***P<0.0001 vs 
untreated cells; ##P<0.001; ###P<0.0001 vs TMZ 100 μM-
treated cells; ΩΩP< 0.001; ΩΩΩP< 0.001 vs TMZ 200 μM-
treated cells) (up to 8000 acquired events for each sample). 
Consistent with the results of cell viability assay, Aldox-
based treatment induced apoptosis in more than 50% of 
U87MG (Figure 2A) and its killing effect against A172 
was reflected in the low number of acquired cells, mostly 
apoptotic cells (Figure 2B).
On the other hand, the apoptotic rate dropped to 
~30% in T98G cells (Figure 2C).
Judging from these data, we further investigated the 
pro-apoptotic effect of Aldox, either alone and combined 
to TMZ, in T98G cells prolonging treatments for 48h. 
At this time point, untreated-, TMZ- and Aldox-treated 
samples have been successfully acquired and analyzed, 
confirming the pro-apoptotic effect of Aldox only, 
while the reliable cytometric evaluation of apoptosis in 
Aldox-TMZ-treated samples was not possible due to the 
unsatisfactory number of acquired events (< 1000 events) 
(data not shown).
Effects of TMZ and Aldox on the P-gp function
We studied the effects of TMZ and Aldox on the 
P-gp ATPase activity, detected as a luciferase-generated 
luminescent signal, and measured in terms of change in 
luminescence and ATP consumed by P-gp.
As shown in the upper panel of Figure 3A, samples 
treated with TMZ and Aldox contained a higher amount 
of ATP compared to Verapamil sample (**P=0.0011), 
reflecting a reduced consumption of ATP by P-gp (lower 
panel, Figure 3A).
The rate of ATP consumption due to Basal P-gp 
ATPase activity (calculated as difference in luminescent 
signal between Na3VO4-treated and untreated samples) 
was 0.010±0.004 while Verapamil stimulated the ATPase 
activity of P-gp with >6-fold stimulation of the basal 
activity.
In the presence of TMZ (both low and high doses) 
and Aldox, P-gp consumed ATP equal to or less than 
basal control (no statistically significant differences) and 
Verapamil-positive control (**P=0.0013), indicating that 
these drugs were able to adversely affect the P-gp ATPase 
activity
Figure 2: Pro-apoptotic effect of Aldox, TMZ and their combination (30 h) on U87MG (A), A172 (B) and T98G (C) cells. Upper panel: 
qualitative representation of TUNEL positivity; lower panel: quantitative representation of TUNEL positivity (mean % TUNEL positivity 
± S.D) **P=<0.001; ***=P<0.0001 vs untreated cells; ##=P<0.001; ###=P<0.0001 vs TMZ 100 μM-treated cells; ΩΩP< 0.001; ΩΩΩP< 0.0001 vs 
TMZ 200 μM-treated cells; ANOVA one-way followed by Bonferroni post-hoc test. Experiments performed two times in triplicate.
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To study the possible P-gp-mediated TMZ-Aldox 
interaction, we also performed uptake experiments on 
MDCKII, parental and P-gp transfected cells, taking 
advantage of Aldox autofluorescence (upper panel, 
Figure 3B).
As expected, the mean fluorescence intensity of 
Aldox in MDCKII parental cells was superior to that of 
MDCKII P-gp cells (47.93 vs 25.30). However, compared 
to untreated P-gp trasfected cells (7.13), the same samples 
exposed to Aldox, as well as to Aldox-TMZ, contained 
a significant higher amount of the anthracycline (25.30, 
***P<0.0001) (lower panel, Figure 3B), indicating its 
inhibitory effect on the efflux pump activity.
The in vivo anti–glioma effects of Aldox-TMZ 
combined therapy
We evaluated Aldox at 16 mg/kg (50% MTD) once 
weekly for up 5 weeks alone and in combination with 
TMZ (0.9 mg/kg, daily administrations).
At the end of treatments (from day 7 to day 42), 
U87–bearing mice treated with Aldox alone showed less 
tumor compared to vehicle, with a bioluminescence (BLI) 
average radiance 2-fold lower than untreated animals. 
On the contrary, the association Aldox-TMZ induced a 
remarkable decrease of tumor growth, with an average 
BLI 4-fold lower than vehicle, which did not differ from 
the effect obtained by the administration of TMZ alone 
(Figure 4A).
On day 42, the mean of IVIS data in TMZ-treated 
mice was 1.93E+05 (P=0.0056 vs vehicle) and in those 
treated with Aldox plus TMZ was 2.43E+05 (P=0.0175 
vs vehicle), to indicate a significant reduction of tumor 
growth compared to vehicle (8,87E+05) (Figure 4B).
In addition, by day 56 (15 days after the end of 
treatments), the tumor sizes in Aldox-, TMZ- and 
Aldox plus TMZ- treated mice were ~4-fold, ~11-fold 
and ~9-fold smaller when compared to controls. The 
treatment with Aldox alone induced a reduction trend 
in tumor growth, although not statistically significant 
compared to vehicle (P=0.0635), while its association 
with TMZ caused a tumor volume inhibition (TVI) of 
about 90% (P=0.0190 vs vehicle) (Figure 4B). This 
effect did not significantly differ from that obtained by 
the administration of TMZ alone (TVI 92%, P=0.0317 
vs vehicle).
Figure 3: (A) Drug stimulated P-gp ATPase activity was estimated by Pgp-GLOassay system and measured in terms of both change in 
luminescence, that reflects the ATP concentration (upper panel), and ATP consumption (nmol ATP consumed/mg P-gp/minute) (lower 
panel), that reflects the P-gp ATPase activity. Data expressed as mean ± SD. Experiments performed two times in triplicate. (B) The uptake 
of Aldox, with or without TMZ, was evaluated in MDCKII parental and P-gp transfected cells by flow cytometry, using the FL2-H channel. 
Upper panel: qualitative representation of flow cytometric detection of Aldox uptake; lower panel: quantitative representation of Aldox 
uptake (Mean Aldox Fluorescence ± S.D), ***=P<0.0001 vs untreated samples; ANOVA one-way followed by Bonferroni post-hoc test. 
Results representative of two independent experiments in triplicate.
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In the plot shown in Figure 4B, the BLI values 
measured after day +56 have been omitted due to a high 
mortality, especially in vehicle and Aldox-treated mice.
The images of BLI acquisition of brain tumors on 
days + 7, + 42 and + 56 are shown in Figure 4C.
Effect of Aldox-TMZ combined therapy on 
survival time of mice bearing GBM tumors
The effect of a combination therapy schedule of 
Aldox and TMZ on mice survival is shown in Figure 5A. 
The study results demonstrated that Aldox improved the 
survival of mice bearing U87-tumors (+12,5% by day 90) 
when compared to vehicle-treated group who died within 
69 days of tumor cell implantation; on the other hand, its 
association with TMZ leaded to an increase of survival 
time with a rate of +37,5% (vs vehicle).
Most interestingly, although the endpoint survival 
percentage was equal between TMZ- and Aldox plus 
TMZ-treated mice (37,5%), the combination therapy 
delayed the mortality observed during the experimental 
period (until day 90) when compared to TMZ alone, 
without side effects which were judged by body weight 
(BW) variations (Figure 5B).
DISCUSSION
Combination regimens of targeted and 
immunotherapies with TMZ have been tested in several 
clinical trials for high grade glioma patients; currently, 
none of these studies has yet reached a significant clinical 
benefit in terms of overall survival or progression free 
survival [13, 14]. Powerful anticancer agents as Dox had 
poor impact on brain tumors [15] due to various resistance 
Figure 4: (A) BLI signals throughout the experimental period, distinctly for group of treatment and day from injection (from day 7 to 
day 42). (B) Average IVIS values between experimental groups at day +42, +49 and +56. Data expressed as mean ± SD. Outliers were 
removed by the ROUT test (Q=1%). Statistical analysis was performed with Mann-Whitney U-Test (**=P<0.01; *=P<0.05). (C) Images of 
BLI acquisition of brain tumor on day 7 (start of treatments), day 42 (end of treatments) and day 56 (15 days after the end of treatments). 
The colorimetric scale represents the range of radiance values (red=highest value; blu=lowest value) which translates to tumor growth.
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mechanisms, including the active efflux of anticancer 
drugs mediated by BBB transporters (specially P-gp). On 
the other hand, agents as TMZ, which has a good BBB 
penetration, have to be administered in high systemic 
doses to achieve therapeutic brain levels because of short 
half-life in plasma [16].
Albumin has been recently described “as an 
attractive candidate for targeted intracellular delivery of 
drugs attached by covalent conjugation, genetic fusions, 
association or ligand-mediated association” [17].
Among albumin-based systems in clinical trials, 
Aldox (the albumin-binding Dox, also known as INNO-
206 or DOXO-EMCH) has been very successful, 
exhibiting a good profile in a phase 3 study in soft tissue 
sarcoma and in phase 2 studies in small cell lung cancer, 
Kaposi’s sarcoma and GBM. It has also been tested in 
combination therapies to treat solid malignancies [10, 
11, 18], encouraging the study of association of albumin-
binding drugs with other anticancer agents.
This study explored the preclinical effectiveness 
of a combination therapy schedule of TMZ and Aldox 
in comparison to the effect of the single agents against 
gliomas in vitro and in vivo.
Based on cell culture experiments, well-known 
TMZ sensitive U87MG and A172 (IC50 < 200μM) [19, 
20] showed reduced viability (Figure 1A and 1B) and high 
apoptotic rate (Figure 2A and 2B) when treated with Aldox 
12 μM (IC50 value at 72h), without significant difference 
among Aldox-TMZ combined treatment and Aldox 
therapy alone. On the other hand, this novel anthracycline 
induced moderate cytotoxic and apoptotic effects (Figure 
1C and 2C) on the TMZ-resistant T98G [19, 20], that we 
have previously demonstrated to be also a Dox-resistant 
cell line [21]. The cytotoxicity became remarkable with 
the co-exposure to TMZ, resulting in a cell viability of 
50% of control and in a significant higher killing effect 
compared to Aldox alone (Figure 1C). Unfortunately, flow 
cytometry performed after 48h of treatments did not allow 
achieving a reliable evaluation of apoptosis in Aldox-TMZ 
groups due to the unsatisfactory number of T98G acquired 
cells (data not shown). This finding was consistent with 
the cellular suffering observed microscopically and it was 
further reflected in the cytotoxicity data recorded at 72h.
We also evaluated the effect of Aldox on P-gp by 
studying its ATPase activity. Some studies have shown a 
synergistic effect on glioma cells for TMZ in association 
with other chemotherapeutic agents, identifying the 
direct negative modulation of P-gp by TMZ as one of the 
possible mechanisms [12, 22]. Our data demonstrated 
an increased ATP concentration (upper panel, Figure 
3A), reflecting a reduced activity by P-gp (lower panel, 
Figure 3A), with addition of Aldox as well as of TMZ 
(no difference among low and high doses). We then 
characterized the intracellular uptake of Aldox and 
analyzed if there was any change after the co-exposure to 
a low dose of TMZ. Based on the results, the co-exposure 
to TMZ did not significantly improve the uptake of Aldox, 
itself able to accumulate in P-gp-overexpressed cells 
(upper panel, Figure 3B) due to a negative regulation of 
the P-gp function. As shown in Figure 3B (lower panel), 
the mean fluorescence intensity of Aldox in MDCKII 
parental cells was superior to that of MDCKII P-gp cells; 
however, compared to untreated P-gp trasfected cells, the 
same samples exposed to Aldox contained a higher amount 
of the anthracycline, unlike the previously observed with 
Dox [23].
Figure 5: (A) Survival curves were compared between mice bearing GBM tumors, treated with vehicle, TMZ, Aldox or Aldox plus TMZ. 
Analysis was performed with Kaplan–Meier test. (B) BW measurements were used to evaluate the drug-related side effects. No statistical 
significant differences were reported between all experimental groups. Data expressed as mean ± SD.
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Finally, to determine whether our in vitro findings 
would translate into anti–glioma effect in vivo, we 
evaluated the Aldox activity in combination with TMZ on 
tumor regression in a xenograft model of human GBM. 
U87-luc cells were injected in the right lobe of the brain 
of Foxn1 nude mice, which received vehicle (saline), 
weekly intravenous injections of Aldox (16 mg/kg), daily 
administrations of TMZ (0.9 mg/kg) or their combination 
for up 5 weeks.
In our U87-xenograft model, the Aldox therapy 
produced a moderate TVI; on the contrary, its association 
with TMZ leaded to a remarkable reduction of tumor 
growth, without significant difference from the effect 
obtained by the administration of TMZ alone.
Whereas the anti-glioma effect of Aldox was 
observable at the end of pharmacological treatment (from day 
35), it is important to note that the combined therapy with 
TMZ was effective from early injections (Figure 4A) and the 
combination of both agents proved still superior with longer 
follow up. From day 42 to day 56 (Figure 4B), the Aldox-
TMZ schedule maintained a reduction trend in tumor growth 
with a TVI of 90% (P=0.0190 vs vehicle) and tumor sizes 
~2-fold smaller than Aldox treated-group (Figure 4C).
Our study confirmed also an improved survival time in 
Aldox-treated animals compared to vehicle group (+12.5% 
by day 90) (Figure 5A), as already shown by Marrero’s 
group [6]. Long-term efficacy and toxicity profile, which 
was judged by BW variations (Figure 5B), were similar to 
those obtained with daily administrations of TMZ 0.9 mg/kg, 
whose anti-glioma effects have been recently demonstrated 
in the same orthotopic xenograft model [24].
Most importantly, the association with TMZ tripled 
the survival rate (+37.5% vs vehicle) and, although the 
endpoint survival percentage was equal between TMZ- 
and Aldox plus TMZ-treated mice, the combined therapy 
delayed the mortality during the experimental period (until 
day 90) when compared to TMZ alone.
Intriguingly, the Aldox dose of 16 mg/kg (48 mg/
m2 [25]) is 4-fold lower than the recommended dose of 
200 mg/m2 in clinical trials [6], and a cumulative TMZ 
dose of 26 mg/kg(78 mg/m2 [25]) is far below the dose of 
75 mg/m2/day used in oncology practice [26], resulting in 
reduced manifestations of drug-related side effects.
Taken together, the data obtained in our preclinical 
model suggest that the association of Aldox and TMZ has 
a better therapeutic efficacy for gliomas comparing to the 
single agents and provide a strong rationale for testing the 
anticancer activity of this combination in clinical studies 
in patients with high-grade gliomas.
MATERIALS AND METHODS
Chemicals and drugs
INNO-206 (Aldox) (MedChem Express, 10 mg and 
100 mg) and TMZ (Sigma Aldrich, 25 mg) were dissolved 
in dimethyl sulfoxide and physiological saline solution for 
in vitro and in vivo test, respectively.
In vitro treatments were performed adjusting the 
drugs with culture medium to the final concentration of 
100 μM and 200 μM for TMZ and 12 μM for Aldox at the 
time of treatment.
For in vivo experiments, TMZ and Aldox were 
prepared on each day of injection at the concentration of 
0.9 mg/kg and 16 mg/kg per injection, then administered 
per os (OS) and intravenously (IV, tail vein), respectively.
Cell lines
Human GBM cell lines U87MG, T98G, A172 
(American Type Culture Collection, ATCC) and parental 
and P-gp transfected Madin-Darby canine kidney 
epithelial cells (MDCKII, Netherlands Cancer Institute, 
Amsterdam) were cultured at 37°C in the presence of 5% 
CO2.
Dulbecco’s modified Eagle’s medium with 10% 
fetal bovine serum was used for all cell lines except for 
U87MG and T98G, maintained in Essential medium 
containing 10% serum.
For establishing the intracranial xenograft 
GBM tumor, U87MG-luc2 cells (PerkinElmer Italia 
S.P.A., Italy), expressing a luciferase reporter gene, 
were maintained in M-199 medium until the time of 
implantation.
Chemotherapeutic sensitivity assay
U87MG (4×104/well), A172 (4×104/well) and 
T98G (3×104/well) cells were plated in 24-well plates 
in triplicate, allowed to attach for 24h and then exposed 
to TMZ, Aldox and their combination at the indicated 
concentrations for 72h.
MTT Cell Proliferation Assay (Cayman Chemical, 
USA) was performed to study cell viability, following the 
manufacturer’s instructions.
A MULTISKAN FC (Thermo Scientific) microplate 
reader at a test wavelength of 550 nm was used to read 
absorbance values.
TUNEL
U87MG (32 × 104 cells/dish 60) and A172 (32 × 104 
cells/ dish 60) cells were cultured for 24h and treated with 
TMZ, Aldox and their combination for 30h; T98G cells (20 
× 104 cells/ dish 60) were exposed to drugs for 30h and 48h.
Samples were then fixed, blocked, permeabilized 
and TUNEL (terminal deoxynucleotidyl transferase–
mediated dUTP nick end labeling) was performed by in 
situ cell death detection kit fluorescein (Roche), following 
the manufacturer’s instructions.
Apoptosis was analyzed by a flow cytometer 
(MACSQuant® Analyzer 10, Miltenyi Biotech), using the 
FlowLogic Software (Inivai Technologies).
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All experiments were performed two times in 
triplicate.
P-gp ATPase activity
Drug stimulated P-gp ATPase activity was estimated 
by Pgp-Glo Assay System (Promega, Madison, WI) and 
measured in the presence of TMZ and Aldox, using the 
GloMax® 96 Microplate Luminometer (Promega).
Experimental studies and data analysis were 
performed according to manufacturer’s guidelines, as 
previously described [24].
Briefly, in a 96 well plate recombinant human P-gp 
was incubated with P-gp-Glo assay buffer™ (control), 
verapamil (positive control), sodium orthovanadate 
(Na3VO4, P-gp ATPase inhibitor), TMZ 100 μM, TMZ 
200 μM and Aldox 12 μM. A luciferase reaction mixture 
initiated an ATP-dependent luminescence reaction, then 
measured in terms of both change in luminescence and 
ATPase activity by interpolation from an ATP standard 
curve.
Luminescence changed in direct proportion to ATP 
concentration and the rate of ATP consumption (nmol ATP 
consumed/mg P-gp/minute) by P-gp was determined as 
difference between the amount of ATP in absence and 
presence of Na3VO4 (Basal P-gp ATPase activity).
All experiments were performed two times in 
triplicate.
Intracellular Aldox accumulation
The cellular uptake of Aldox was analyzed using a 
FACScan flow cytometer (Becton Dickinson, Mountain 
View, CA, USA), equipped with a 488 nm argon laser. 
The exponentially growing parental and P-gp transfected 
MDCKII cells were treated with indicated concentrations 
of TMZ, Aldox and their combination at 37°C for 2 h, 
according to the previously described method [23].
Aldox fluorescence was determined in 8000 events 
for each sample.
Xenograft study
GBM tumors were induced in 80 Foxn1 nude male 
mice, 6 weeks-old, by implantation of 3x105 U87MG-luc 
cells in the right lobe of the brain.
One week after tumor implantation, 64 animals were 
randomly assigned to four groups (16 mice/group) to be 
treated with different drugs, as follow:
- Group 1 (vehicle): weekly intravenous (IV) 
administration of physiologic solution, i.e., 7, 14, 21, 28, 
35 days.
- Group 2: daily oral (OS) administration of TMZ 
0.9 mg/kg, from day 7 to day 35.
- Group 3: weekly administration of Aldox 16 mg/kg 
(50% MTD), IV, i.e., 7, 14, 21, 28, 35 days.
- Group 4: TMZ-Aldox combination for up five 
weeks.
At the end of treatments (day 42, one week after 
the last injection), 32 animals were sacrified by CO2 
inhalation; the remaining mice (8 animals/group) were 
observed for mortality until the 90th day of the study.
BW measurements were carried out 2 times a 
week and BLI imaging acquisition (IVIS spectrum 
image system, Perkin Elmer) were performed at day 0 
(immediately after tumor implantation), at day 3 and then 
weekly until the end of the experiment (day 90).
A BW loss ≥ 15% has been considered as sign of 
suffering, involving the mouse sacrifice.
All experiments were conducted in accordance 
with the Institutional Animal Care and Use Committee 
guidelines.
The state of health of animals has been observed 
daily; if clinical signs showed clear suffering status, 
mice have been sacrificed under the veterinary and study 
director approval.
Statistical analysis
Data shown represent mean ± SD. Analyses were 
carried out using GraphPad Prism 5.
Radiance data were analyzed by Mann-Whitney U-
test at the indicated time points. The ROUT test (Q=1%) 
was used to remove outliers.
Survival analysis was performed by Kaplan–Meier 
curves and the log-rank test.
All in vitro experiments were repeated two or three 
times in triplicate and one-way ANOVA with a post hoc 
analysis by the Bonferroni t-test was used for multiple 
comparisons.
Significance was determined at P<0.05.
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